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Abstract 
Background: There is no known effective therapy for patients with COVID-19. Initial 
reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin 
(HY/AZ) have resulted in massive adoption of this combination worldwide. However, 
while the true efficacy of this regimen is unknown, initial reports have raised 
concerns regarding the potential risk of QT prolongation and induction of torsade de 
pointes (TdP).  
Objective: to assess the change in QTc interval and arrhythmic events in patients 
with COVID-19 treated with HY/AZ  
Methods: This is a retrospective study of 251 patients from two centers, diagnosed 
with COVID-19 and treated with HY/AZ. We reviewed ECG tracings from baseline and 
until 3 days after completion of therapy to determine the progression of QTc and 
incidence of arrhythmia and mortality. 
Results: QTc prolonged in parallel with increasing drug exposure and incompletely 
shortened after its completion. Extreme new QTc prolongation to > 500 ms, a known 
marker of high risk for TdP had developed in 23% of patients. One patient developed 
polymorphic ventricular tachycardia (VT) suspected as TdP, requiring emergent 
cardioversion. Seven patients required premature termination of therapy. The 
baseline QTc of patients exhibiting extreme QTc prolongation was normal.   
Conclusion: The combination of HY/AZ significantly prolongs the QTc in patients with 
COVID-19. This prolongation may be responsible for life threating arrhythmia in the 
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form of TdP. This risk mandates careful consideration of HY/AZ therapy in lights of its 
unproven efficacy. Strict QTc monitoring should be performed if the regimen is 
given.   
Introduction 
The evidence supporting effective drug therapy for COVID-19 is limited. In vitro 
studies have suggested that Hydroxychloroquine alone and in combination with 
Azithromycin could be a viable therapy 
1, 2
. A small, controversial study enrolling 26 
treated patients and 16 non-randomized controls showed that HY/AZ shortened the 
viral shedding of SARS-CoV-2 
3
. Based on this, clinicians in many countries have 
begun using these medications, and multiple randomized trials are ongoing 
4
. 
However, HY and AZ have each been independently shown to increase the risk for 
QT interval prolongation, drug-induced torsade de pointes (TdP), and sudden cardiac 
death (SCD) 
5-8
. We recently reported QT prolongation in a preliminary series of 84 
patients with COVID-19 treated with HY/AZ 
9
. Here we report a study from two 
centers evaluating the effects of HY/AZ on the QT interval and the arrhythmic risk in 
patients with COVID-19. 
Methods 
This is a retrospective study including 251 consecutive adult patients hospitalized at 
NYU Langone Health (211 patients) and at San Paolo University Hospital (40 patients) 
with COVID-19 disease, treated with the combination of HY/AZ. Patients with a 
baseline ECG and at least one ECG performed after medication administration were 
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included. Of 325 patient screened, we excluded 40 (12.3%) patients without baseline 
ECG and 34 (10.4%) patients without follow up ECG. 
Of the 211 patients from the NYU site, 84 were reported in our recent publication 
9
. 
Hydroxychloroquine was given orally at 400 mg BID for one day (loading dose) 
followed by 200 mg BID for 4 days. Azithromycin was given orally at a dose of 500 
mg daily for 5 days.  For QTc measurement, five cardiologists trained and 
experienced in QT measurement performed all electrocardiographic measurements. 
The QT interval was measured using the “Tangent” method 
10
. Briefly, a tangent is 
drawn to the steepest last limb of the presumed T-wave to define the end of the T-
wave as the intersection of this tangent with the baseline. QTc was calculated from 
the QT and RR intervals using the Bazetts’ formula. The QRS interval was measured 
from the onset of the Q wave, or R wave if no Q wave was visible, to the J point. JTc 
interval was calculated by subtracting the QRS duration from the QTc interval (QTc – 
QRS). 
For quality assurance, QT measurements were validated by a senior 
electrophysiologist experienced in QT measurements who repeated the 
measurement at arbitrary times, corroborating ~10% (100/978) of 
all QT measurements. This validation showed very high agreement between 
measurements, with a correlation coefficient of R=0.95 (p<0.01). The closing date of 
follow-up was April 15
th
 2020. The primary endpoint was extreme QTc prolongation. 
This included absolute QTc >500ms (or JTc >410ms to adjust for patients with 
QRS>120 ms),  known marker of high risk for malignant arrhythmia and sudden 
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cardiac death 
11-13
, or QTc prolongation of >60 ms, another high risk marker 
regardless of baseline QRS
14, 15
. 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 26, and figures were 
constructed using GraphPad Prism 8. Continuous variables are expressed as mean ± 
standard deviation, and categorical variables are expressed as percentages (95% 
confidence interval). Normality of data samples was assessed using Shapiro-Wilk 
test. Two sample hypothesis testing for continuous variables was performed using 
Student’s t-test if samples had normal distributions, Mann-Whitney U test if samples 
did not have normal distributions, or paired samples t-test for paired samples. Two 
sample hypothesis testing for categorical variables was performed using Fisher’s 
exact test. For Figure 2A, a mixed-effects analysis with Geisser-Greenhouse 
correction was performed, followed by Dunnett’s multiple comparisons test to 
compare each day’s QTc to the baseline QTc. For Figure 2B, one sample t-test (if 
samples were normally distributed) or one sample Wilcoxon signed rank test (if 
samples were not normally distributed) was performed to compare each sample 
against a delta QTc of 0 ms (i.e. no change from baseline), and p values were 
adjusted using the Holm-Bonferroni method to α < 0.05. Univariate and multivariate 
logistic regression were performed to identify predictors of prolonged JTc, delta QTc, 
and QTc. The univariate predictors with p < 0.05 and greatest clinical utility were 
selected for subsequent multivariate analysis, as allowed by our sample size. 
The study was performed according to the NYU Institutional Review Board and 
Quality Improvement initiative and the University Hospital of Milan Institutional 
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Review Board guidance in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments. 
Results 
We included 251 patients in our cohort with a maximal follow up of 8 days and mean 
ECG follow up time of 5.2 ± 2 days (Table 1). The median age was 64±13 years and 
75% were male. Forty four (17.5%) patients died of respiratory or multi-organ 
failure. One patient with extreme QTc prolongation developed TdP and required 
emergent cardioversion (Figure 1), representing an arrhythmic risk of 0.4%. QTc 
interval prolonged from a baseline of 439 ± 29 ms to a maximal value of 473 ± 36 ms 
(p<0.001) which occurred on day 4.1 ± 2 of therapy) in the general cohort (Figure 2). 
JTc prolonged from a baseline of 342±25 ms to a maximal value of 375±35 ms which 
occurred on day 4.1±1.9. For patients with QRS < 120 ms, QTc prolonged from a 
baseline of 434 ± 25 to a maximum of 469 ± 34 ms, which occurred on day 4 ± 1.9.  
The individual change between baseline and maximal QTc is presented in figure 3. 
Figure 4 represents the distribution of QTc ranges at each day. Of note, In 58 of 251 
(23%) patients, at least one measure of extreme QTc prolongation was observed. 
Specifically, QTc>500 msec was seen in 28 of 222 (13%) patients with QRS<120. 
JTc>410 was seen in 4 of 29 (14%) patients with QRS >120, and ΔQTc>60 was seen in 
51 of 251 (20%) patients with any QRS. These numbers include 25 patients who had 
more than one of these endpoints.  Thirty five (60%) of the 58 patients who met the 
composite endpoint were not on any other QTc prolonging medication. In this high 
risk group, QTc increased from a baseline of 431 ± 32 to 513 ± 38 ms and JTc 
increased from 335±28 to 417± ms (p<0.01 for both). In 8 patients, extreme QTc 
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prolongation triggered discontinuation of therapy prematurely, including the patient 
who developed TdP where therapy was halted on day 4. In 29 (11.5%) patients, 
baseline QRS was more than 120 ms. The baseline JTc and the maximal ∆JTc were 
similar between patients with and without QRS>120 (Table 2). On multivariate 
analysis, baseline QTc and co-administration of Amiodarone were significant 
predictors of QTc > 500 ms, while baseline Creatinine and co-administration of 
Amiodarone were predictors of ∆QTc > 60 ms (Tables  3 and 4). The predictors of 
extreme JTc prolongation > 410 ms included baseline JTc and Creatinine 
(Supplementary Table 1). Patients with extreme QTc prolongation had lower body 
weight, greater frequency of kidney disease, and greater Amiodarone exposure 
(Supplementary Table 2).   
 
Discussion 
Drug-induced QT prolongation is an important substrate for TdP, a potentially lethal 
polymorphic VT. In our study of 251 patients with COVID-19, we found high 
incidence of QTc prolongation, with at least one documented polymorphic VT 
(suspected TdP) for a rate of 0.4%. To put the incidence of TdP in perspective, the 
risk of TdP induction by Sotalol is estimated at 0.1% 
16
. Due to this risk, Sotalol is 
introduced under ECG monitoring in the hospital for at least 3 days. In our study, we 
observed QTc prolongation in parallel with increasing HY/AZ exposure, which 
partially shortened after medication cessation. For example, the proportion of 
patients with QTc > 500 ms was 20% at day 4 after completion of HY/AZ therapy and 
declined to 10% one day later. Baseline QTc/JTc, Creatinine level and co-
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administration of Amiodarone were significant predictors of extreme QTc/JTc 
prolongation and ∆QTc > 60 ms. We show that the effect on the QTc was driven 
entirely by prolonging the repolarization and regardless of QRS, as evident by the 
corresponding JTc prolongation. In this regard, it is worth mentioning that there is 
limited data regarding high arrhythmic risk markers in patients with QRS >120 ms 
and QTC prolongation. We utilized QTc change by > 60 ms as a marker, a cutoff that 
was initially proposed in an algorithm designed to automatically detect QTc 
prolongation taking into account the normal variation in QTc 
17
. In addition we 
utilized a cutoff of JTc>410 ms as the correlate of  QTc>500 ms for patients with wide 
QRS, based on the deduction of the mean QRS value we found in our patients with 
normal QRS, which was 90 ms. Previous information on the potential proarrhythmic 
effect of the combination Chloroquine/Hydroxychloroquine and Azithromycin is 
limited. In a randomized, placebo-controlled parallel trial in 116 young healthy 
controls receiving Chloroquine alone or in combination with Azithromycin, co-
administration increased the QTc interval (Fridericia) by up to 14 ms 18, 19. However, 
the risk for drug induced TdP is substantially higher in hospitalized patients. This, is 
due to greater prevalence of other risk factors for TdP, including older age, presence 
of underlying heart disease, genetic factors 
20
, electrolyte disturbances and co-
treatment with other QT prolonging medications 
21-24
. Indeed, in a recent study 
assessing Chloroquine therapy in COVID-19 patients, extreme QT prolongation and 
excess cardiac mortality in the higher dose arm led to premature interruption of the 
regimen 
25
. Concordantly, recently published studies confirmed a QT prolonging 
effect of HY/AZ ranging between 23 to 41 ms (Supplementary Table 3). In the current 
study, we found a significant proportion of patients with extreme QTc prolongation, 
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23%, with at least one polymorphic VT requiring cardioversion. Another 7 patients 
who developed extreme QTc prolongation by day 3 had the treatment stopped, 
possibly preventing additional arrhythmic events. Interestingly, the coupling interval 
of the arrhythmia initiating beat observed in our study was ~380 ms, which is shorter 
than expected for TdP 
26
. In this regard, Azithromycin has been shown to induce 
short-coupled polymorphic VT regardless of QT prolongation 
27
. It is thus impossible 
to be certain about the nature of the arrhythmia. Since this polymorphic VT took 
place at the time of significant QT prolongation, it is reasonable to assume that 
HY/AZ played an important pro-arrhythmic role. However, in view of its relatively 
short coupling interval, it is not clear if this is true TdP or a polymorphic VT triggered 
by Azithromycin via increased sodium current.  The alarming proportion of COVID-19 
patients developing extreme QT prolongation with HY/AZ therapy in our study can 
be explained by the specific characteristics of this population, which includes older 
age, greater prevalence of underlying and acute renal failure and co-administration 
of additional QT prolonging medications, particularly Amiodarone.   
Recently published guidance statements addressing QTc surveillance and arrhythmic 
risk in COVID-19 patients are based on LQTS risk stratification principals and include 
pretreatment assessment of the QTc, considering stopping other QTc prolonging 
medications, and providing special attention to those with highest risk features 
15, 28, 
29
. Yet, our findings suggest that risk stratification of patients with COVID19 may be 
more complex. For example, we found that the baseline QTc in patients with 
extreme QTc prolongation was only 431 ± 32 ms, within the “normal” QTc range. 
Moreover, 42 (72%) of the 58 patients in the high risk group had a baseline QTc <450 
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and JTc < 350 ms. Additionally, it is important to consider that even careful 
monitoring of the QT interval may only partially mitigate the risk for TdP. This is 
because arrhythmia often occurs in the setting of sudden, intermittent changes in 
the R-R interval, such as when PVCs, APCs or pauses occur. In these cases, TdP can 
present even if the QTc in only mildly prolonged at baseline 
30
. We therefore suggest 
that individual risk/benefit assessment should be applied before treating with HY/AZ. 
We recommend daily ECG monitoring, with reassessment of the therapy if high risk 
markers appear (QTc >500 ms or ∆QTc > 60 ms). For this, triggered alerting systems 
may be applied 
31
. Finally, we observed only partial resolution of the QTc at 3 days 
after completion of therapy. This may be attributed to the prolonged half-life of 
Hydroxychloroquine, which is approximately 20 days. This finding requires special 
attention when considering discharging patients receiving HY/AZ or if outpatient 
treatment with HY/AZ is planned.  
Conclusions 
Treatment of COVID-19 with HY/AZ prolongs the QTc to an extreme degree in a 
significant proportion of patients, increasing the risk for TdP. Risk/benefit 
considerations should be carefully and individually evaluated and preventive 
measures should be applied when using this regimen.  
Limitations  
Our study has several limitations. This is an observational, retrospective study. We 
did not include patients treated with each medication separately and each patient 
served as a self-control. Patients without baseline or follow up ECG were excluded 
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from analysis, which can represent a bias. This is partially mitigated by the 
consecutive inclusion of patients meeting study criteria. The population in our study 
was primarily Caucasian, thus applicability to other populations warrants further 
study. Relatively short follow-up time after HY/AZ regimen completion was available. 
We did not assess serum drug concentrations.  
 
 
Figure legends: 
 
Figure 1: QTc prolongation and Torsdaes de point. This 68-year-old male patient, 
without any past medical history was found to be positive for SARS-COV 2 and HY/AZ 
was initiated. The patient did not receive any other QT prolonging medications. 
Baseline ECG is presented in panel A. ECG before the initiation of HY/AZ. QTc = 447 
ms. QTc prolonged gradually to 477 ms on day 1, 480 ms on day 2 and 505 ms on day 
3. In panel B, ECG at day 4 of HY/AZ revealed QTc prolongation to 546 ms. C. The 
same night, multiple short runs of TdP were noted on telemetry. HY/AZ was stopped, 
the patient developed TdP requiring cardioversion which was given in <10s due to 
incidental presence of a physician by the patient. Laboratory from day 4 revealed 
Creatinine 1.1 (mg/dL), K – 3.5 (mEq/L) and mildly elevated liver function tests. 
Figure 2: A. Daily absolute QTc in patients treated with HY/AZ and B. change in QTc 
by day. Number of patients, mean QTc +/- SD are presented at each day. * 
represents p<0.01 for the comparison with baseline QTc. Blue lines indicate end of 
HY/AZ therapy.  
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Figure 3: Individual QTc changes from baseline to the individual maximal QTc. In A, 
patient with maximal QTc>500 ms are marked in red. In B, patients with ∆QTc>60 ms 
are marked in red.  
Figure 4: Distribution of QTc ranges by day of therapy. Note that therapy was given 
on days 1-5 (dashed line).      
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Tables: 
Table 1. Baseline Characteristics. N=251 
Age (yrs) 64 ± 13 
Gender (% male) 75% (70% - 81%) 
Weight (kg) 86.0 ± 17.9 
    
Coronary artery disease 12% (8% - 16%) 
Hypertension 54% (48% - 60%) 
Chronic kidney disease 11% (7% - 15%) 
Diabetes mellitus 27% (21% - 32%) 
Chronic obstructive pulmonary disease 7% (4% - 10%) 
Congestive heart failure 3% (1% - 5%) 
    
Creatinine at initiation (mg/dL) 1.2 ± 0.9 
Creatinine at max QTc (mg/dL) 1.6 ± 1.5 
CrCl at initiation (mL/min) 84 ± 43 
CrCl at max QTc (mL/min) 80 ± 52 
Abnormal LFTs at initiation 21% (16% - 27%) 
Abnormal LFTs at max QTc 38% (27% - 48%) 
Potassium at baseline (mEq/L) 4.1 ± 0.6 
Potassium at max QTc (mEq/L) 4.2 ± 0.5 
    
QTc-prolonging medications   
Psychiatric medications 12% (8% - 16%) 
Anti-microbials 10% (7% - 14%) 
Amiodarone 9% (6% - 13%) 
    
# QTc-prolonging medications 0.3 ± 0.5 
   0 medications 71% (65% - 77%) 
   1 medication 27% (22% - 33%) 
   2 medications 2% (0% - 4%) 
    
Baseline QTc (ms) 439 ± 29 
Maximum QTc (ms) 473 ± 36 
Maximum delta QTc (ms) 34 ± 35 
Day of maximum QTc 4.1 ± 2.0 
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Baseline JTc (ms) 342 ± 25 
Maximum JTc (ms) 375 ± 35 
Maximum delta JTc (ms) 33 ± 36 
Day of maximum JTc 4.1 ± 1.9 
Mortality 20% (14% - 25%) 
 
 
 
 
 
Table 2. Characteristics by Baseline QRS. N=251 
 Baseline QRS <120ms 
(n = 222) 
Baseline QRS 
≥120ms 
(n = 29) 
p 
Age (yrs) 63 ± 13 73 ± 9 <0.01 
Gender (% male) 75% (70% - 81%) 76% (59% - 92%) 1 
Weight (kg) 85.8 ± 17.5 87.7 ± 21.1 0.54 
        
Coronary artery disease 10% (6% - 14%) 21% (5% - 36%) 0.12 
Hypertension 53% (47% - 60%) 59% (40% - 78%) 0.69 
Chronic kidney disease 9% (6% - 13%) 21% (5% - 36%) 0.10 
Diabetes mellitus 24% (18% - 30%) 48% (29% - 68%) 0.01 
Chronic obstructive 
pulmonary disease 8% (4% - 11%) 3% (-4% - 11%) 
0.70 
Congestive heart failure 1% (0% - 3%) 14% (0% - 27%) <0.01 
        
Creatinine at initiation 
(mg/dL) 1.2 ± 0.9 1.6 ± 1.4 0.01 
Creatinine at max QTc 
(mg/dL) 1.6 ± 1.5 1.7 ± 0.9 0.02 
CrCl at initiation (mL/min) 87 ± 43 65 ± 35 0.01 
CrCl at max QTc (mL/min) 82 ± 53 59 ± 36 0.03 
Abnormal LFTs at initiation 22% (17% - 28%) 15% (0% - 29%) 0.46 
Abnormal LFTs at max QTc 40% (28% - 52%) 19% (3% - 34%) 0.23 
Potassium at baseline 
(mEq/L) 4.1 ± 0.6 4.2 ± 0.4 0.65 
Potassium at max QTc 
(mEq/L) 4.2 ± 0.5 4.0 ± 0.4 0.16 
        
QTc-prolonging medications       
Psychiatric medications 11% (7% - 15%) 17% (3% - 32%) 0.35 
Anti-microbials 11% (7% - 15%) 7% (-3% - 17%) 0.75 
Amiodarone 8% (4% - 11%) 21% (5% - 36%) 0.04 
        
# QTc-prolonging 
medications 0.3 ± 0.5 0.4 ± 0.6 
0.12 
   0 medications 73% (67% - 78%) 59% (40% - 78%) 0.13 
   1 medication 26% (20% - 31%) 38% (19% - 57%) 0.18 
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   2 medications 2% (0% - 4%) 3% (-4% - 11%) 0.46 
        
Baseline QTc (ms) 434 ± 25 475 ± 33 <0.01 
Maximum QTc (ms) 469 ± 34 503 ± 39 <0.01 
Maximum delta QTc (ms) 35 ± 35 29 ± 40 0.43 
Day of maximum QTc 4.0 ± 1.9 4.8 ± 2.2 0.05 
        
Baseline JTc (ms) 344 ± 24 333 ± 26 0.06 
Maximum JTc (ms) 377 ± 35 363 ± 33 0.01 
Maximum delta JTc (ms) 33 ± 36 30 ± 39 0.52 
Day of maximum JTc 4.0 ± 1.9 4.7 ± 2.3 0.13 
        
Number of follow-up ECGs 2.9 ± 1.3 3.2 ± 1.5 0.33 
Follow-up time (days) 5.2 ± 2.0 5.8 ± 1.9 0.09 
 
Table 3. Predictors of Maximum QTc ≥500ms. N=40/251 (16%) 
Univariate Logistic Regressions 
Variable p value OR 95% CI 
Age (years) 0.62 1.01 .98 - 1.03 
Gender (% male) 0.25 1.66 .7 - 3.97 
Weight (kg) 0.25 0.99 .97 - 1.01 
     
Coronary artery disease 0.21 1.82 .72 - 4.61 
Hypertension 0.87 1.06 .54 - 2.09 
Chronic kidney disease 0.05 2.53 1.02 - 6.26 
Diabetes mellitus 0.20 1.61 .78 - 3.3 
Chronic obstructive pulmonary disease 0.93 1.06 .29 - 3.84 
Congestive heart failure 0.01 7.70 1.66 - 35.87 
     
Creatinine at initiation (mg/dL) 0.01 1.79 1.2 - 2.69 
Creatinine at max QTc (mg/dL) <0.01 1.35 1.12 - 1.63 
CrCl at initiation (mL/min) 0.04 0.91 .84 - 1. 
CrCl at max QTc (mL/min) <0.01 0.88 .8 - .95 
Abnormal LFTs at initiation 0.72 1.16 .51 - 2.64 
Abnormal LFTs at max QTc 0.42 0.74 .35 - 1.55 
Potassium at baseline (mEq/L) 0.61 0.84 .42 - 1.65 
Potassium at max QTc (mEq/L) 0.86 0.94 .44 - 1.99 
     
Psychiatric medications 0.21 1.82 .72 - 4.61 
Anti-microbials 0.94 0.96 .31 - 2.94 
Amiodarone <0.01 5.08 2.05 - 12.61 
# QTc-prolonging medications 0.01 2.40 1.31 - 4.38 
    
Baseline QTc (ms) <0.01 1.32 1.16 - 1.51 
Number of follow-up ECGs <0.01 2.05 1.54 - 2.73 
Follow-up time (days) 0.01 1.28 1.06 - 1.55 
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Multivariate Logistic Regression 
Variable p value OR 95% CI 
Congestive heart failure 0.53 1.79 .3 - 10.65 
Creatinine at initiation (mg/dL) 0.06 1.54 .99 - 2.4 
Amiodarone 0.02 3.27 1.18 - 9.11 
Baseline QTc (ms) <0.01 1.26 1.09 - 1.45 
 
 
 
 
 
Table 4. Predictors of Maximum Delta QTc ≥60ms. N=51/251 (20%) 
Univariate Logistic Regressions 
Variable p value OR 95% CI 
Age (yrs) 0.18 1.02 .99 - 1.04 
Gender (% male) 0.56 1.25 .59 - 2.61 
Weight (kg) 0.03 0.98 .96 - 1. 
        
Coronary artery disease 0.05 2.32 1.01 - 5.37 
Hypertension 0.15 1.59 .84 - 2.98 
Chronic kidney disease 0.08 2.17 .91 - 5.16 
Diabetes mellitus 0.23 1.50 .77 - 2.92 
Chronic obstructive pulmonary disease 0.69 0.77 .21 - 2.77 
Congestive heart failure 0.59 1.59 .3 - 8.45 
        
Creatinine at initiation (mg/dL) 0.04 1.38 1.02 - 1.87 
Creatinine at max QTc (mg/dL) 0.01 1.27 1.05 - 1.52 
CrCl at initiation (mL/min) 0.07 0.93 .86 - 1.01 
CrCl at max QTc (mL/min) <0.01 0.90 .83 - .96 
Abnormal LFTs at initiation 0.26 0.62 .27 - 1.42 
Abnormal LFTs at max QTc 0.39 0.76 .4 - 1.43 
Potassium at baseline (mEq/L) 0.22 1.49 .79 - 2.82 
Potassium at max QTc (mEq/L) 0.24 1.52 .76 - 3.04 
        
Psychiatric medications 0.59 1.29 .52 - 3.21 
Anti-microbials 0.71 1.20 .46 - 3.16 
Amiodarone 0.01 3.51 1.44 - 8.55 
# QTc-prolonging medications 0.03 1.88 1.07 - 3.31 
        
Baseline QTc (ms) <0.01 0.78 .69 - .89 
Number of follow-up ECGs <0.01 1.82 1.41 - 2.34 
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Follow-up time (days) <0.01 1.44 1.2 - 1.74 
Multivariate Logistic Regression 
Variable p value OR 95% CI 
Weight (kg) 0.11 0.98 .96 - 1. 
Creatinine at initiation (mg/dL) 0.02 1.73 1.1 - 2.7 
Amiodarone <0.01 5.47 1.87 - 16.02 
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